On August 14, PHARMARON fell 3.22% in regular trading, trading at 29.56 HKD/share, with turnover of approximately 82.26 million HKD.

On the news front, the CXO sector came under broad selling pressure following a sustained prior rally. Within the sector, WuXi AppTec declined 3.30%, GenScript Biotech fell 3.31%, and Insilico dropped 3.84%, indicating a sector-wide correction. At the company level, the controlling shareholder and concert parties had previously announced plans to reduce their combined holdings by up to 2.33%. Additionally, Norges Bank sold 2.8013 million shares on August 7 at approximately 27.23 HKD per share, totaling around 76.28 million HKD, reducing its stake to 4.49%. The confluence of institutional and major shareholder selling pressure weighed on short-term market sentiment, despite the company's upcoming board meeting on August 20 to review interim results, with previously guided first-half revenue growth of 16%-19% year-over-year and new order growth exceeding 30%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)